IVRN Stock Overview
A medical bioscience company that develops technology in regenerative medicine for limb salvage. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Innoveren Scientific Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.00001 |
| 52 Week High | US$0.53 |
| 52 Week Low | US$0.00001 |
| Beta | 483.14 |
| 11 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | -100.00% |
| 33 Year Change | -100.00% |
| 5 Year Change | -100.00% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| IVRN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | n/a | 4.3% | 1.6% |
| 1Y | -100.0% | 18.8% | 32.3% |
Return vs Industry: IVRN underperformed the US Biotechs industry which returned 18% over the past year.
Return vs Market: IVRN underperformed the US Market which returned 32.4% over the past year.
Price Volatility
| IVRN volatility | |
|---|---|
| IVRN Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: IVRN's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine IVRN's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 2 | Michael Yurkowsky | innoverenscientific.com |
Innoveren Scientific Inc., a medical bioscience company that develops technology in regenerative medicine for limb salvage. It is also developing immunotherapies for ovarian cancer, pancreatic cancer, and mesothelioma. The company was formerly known as H-CYTE, Inc. and changed its name to Innoveren Scientific Inc. in July 2023.
Innoveren Scientific Inc. Fundamentals Summary
| IVRN fundamental statistics | |
|---|---|
| Market cap | US$81.00 |
| Earnings (TTM) | -US$3.26m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs IVRN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IVRN income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$999.00 |
| Gross Profit | -US$999.00 |
| Other Expenses | US$3.26m |
| Earnings | -US$3.26m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.40 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -40.6% |
How did IVRN perform over the long term?
See historical performance and comparison